← All trials
NCT05813561
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 30, 2021
- Primary completion
- Jul 23, 2022
- Completion date
- Feb 17, 2023
- First posted
- Apr 14, 2023
- Last posted
- Apr 14, 2023
- Enrollment
- 332
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Daewoong Pharmaceutical Co. LTD.Lead sponsor
- Sun Yat-Sen UniversityStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.